Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy

被引:28
|
作者
Camara-Costa, Hugo [1 ]
Resch, Anika [2 ]
Kieffer, Virginie [3 ]
Lalande, Clemence [4 ]
Poggi, Geraldina [5 ]
Kennedy, Colin [6 ]
Bull, Kim [6 ]
Calaminus, Gabriele [7 ]
Grill, Jacques [4 ]
Doz, Francois [8 ,9 ]
Rutkowski, Stefan [2 ]
Massimino, Maura [10 ]
Kortmann, Rolf-Dieter [11 ]
Lannering, Birgitta [12 ]
Dellatolas, Georges [1 ]
Chevignard, Mathilde [13 ,14 ]
机构
[1] INSERM, Natl Inst Hlth & Med Res, U1178, Paris, France
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] St Maurice Hosp, St Maurice, France
[4] Inst Gustave Roussy, Villejuif, France
[5] IRCCS Eugenio Medea, Sci Inst, Bosisio Parini, Lecco, Italy
[6] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England
[7] Univ Munster, Paediat Oncol, D-48149 Munster, Germany
[8] Inst Curie, Paris, France
[9] Univ Paris 05, Sorbonne Paris Cite, Paris, France
[10] Fdn IRCCS, Ist Nazl Tumori, Milan, Italy
[11] Univ Leipzig, Dept Radiat Therapy, D-04109 Leipzig, Germany
[12] Univ Gothenburg, Paediat Oncol, Gothenburg, Sweden
[13] St Maurice Hosp, Rehabil Dept Children Acquired Neurol Injury, St Maurice, France
[14] UPMC Univ Paris, Univ Paris 04, INSERM, CNRS, Paris, France
关键词
QUALITY-OF-LIFE; PRIMITIVE NEUROECTODERMAL TUMORS; BRAIN-TUMORS; WHITE-MATTER; NEUROCOGNITIVE DEFICITS; CRANIAL RADIATION; CHILDHOOD; RADIOTHERAPY; SURVIVORS; IRRADIATION;
D O I
10.1016/j.ijrobp.2015.04.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: In the European HIT-SIOP PNET4 randomized controlled trial, children with standard risk medulloblastoma were allocated to hyperfractionated radiation therapy (HFRT arm, including a partially focused boost) or standard radiation therapy (STRT arm), followed, in both arms, by maintenance chemotherapy. Event-free survival was similar in both arms. Previous work showed that the HFRT arm was associated with worse growth and better questionnaire-based executive function, especially in children < 8 years of age at diagnosis. Therefore, the aim of this study was to compare performance-based cognitive outcomes between treatment arms. Methods and Materials: Neuropsychological data were collected prospectively in 137 patients. Using the Wechsler Intelligence Scales, Kaufman Assessment Battery for Children, and Raven's Progressive Matrices, we estimated full-scale intelligence quotient (FSIQ) and, when available, verbal IQ (VIQ), performance IQ (PIQ), working memory index (WMI), and processing speed index (PSI). Results: Among the 137 participants (HFRT arm n=71, STRT arm n=66, 63.5% males), mean (+/- SD) ages at diagnosis and assessment respectively were 9.3 (+/- 3.2) years of age (40.8% < 8 years of age at diagnosis) and 14.6 (+/- 4.3) years of age. Mean (+/- SD) FSIQ was 88 (+/- 19), and mean intergroup difference was 3.88 (95% confidence interval: -2.66 to 10.42, P = .24). No significant differences were found in children > 8 years of age at diagnosis. In children < 8 years of age at diagnosis, a marginally significant trend toward higher VIQ was found in those treated in the HFRT arm; a similar trend was found for PSI but not for PIQ, WMI, or FSIQ (mean intergroup differences were: 12.02 for VIQ [95% CI: 2.37-21.67; P=.02]; 3.77 for PIQ [95% CI: -5.19 to 12.74; P>.10]; 5.20 for WMI [95% CI: -2.07 to 12.47; P>.10]; 10.90 for PSI [95% CI: -1.54 to 23.36; P=.08]; and 5.28 for FSIQ [95% CI: -4.23 to 14.79; P>.10]). Conclusions: HFRT was associated with marginally higher VIQ in children < 8 years of age at diagnosis, consistent with a previous report using questionnaire- based data. However, overall cognitive ability was not significantly different. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:978 / 985
页数:8
相关论文
共 50 条
  • [31] A Randomized Trial on Accelerated Versus Standard Small-margin Radiation Schedule in Patients With Prostate Cancer Treated With Combined Brachytherapy and External Beam Radiation Therapy: Toxicity Outcomes and Patterns of Prostate Movement
    Olsen, Johan Staby
    Valachis, Antonios
    Johansson, Bengt
    ADVANCES IN RADIATION ONCOLOGY, 2025, 10 (04)
  • [32] Randomized clinical trial of extended versus standard azathioprine maintenance therapy in newly diagnosed PR3-ANCA positive vasculitis patients at high-risk for disease relapse
    De Joode, A. A. E.
    Sanders, J. S.
    Tervaert, J. W. Cohen
    Stegeman, C. A.
    PRESSE MEDICALE, 2013, 42 (04): : 680 - 680
  • [33] SORAFENIB VERSUS PLACEBO IN ADDITION TO STANDARD THERAPY IN YOUNG PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS FROM 264 PATIENTS TREATED IN THE RANDOMIZED-CONTROLLED SORAML TRIAL
    Roellig, C.
    Mueller-Tidow, C.
    Huettmann, A.
    Kunzmann, V.
    Baldus, C.
    Brandts, C.
    Kraemer, A.
    Schaefer-Eckart, K.
    Neubauer, A.
    Krausel, S.
    Giagounidis, A.
    Aulitzky, W.
    Krug, U.
    Bornhaeuser, M.
    Schaich, M.
    Parmentier, S.
    Thiede, C.
    von Bonin, Malte
    Schetelig, Johannes
    Kramer, Michael
    Serve, Hubert
    Berdel, Wolfgang E.
    Ehninger, Gerhard
    HAEMATOLOGICA, 2013, 98 : 248 - 249
  • [34] Sorafenib versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SORAML Trial
    Roellig, C.
    Mueller-Tidow, C.
    Huettmann, A.
    Noppeney, R.
    Kunzmann, V.
    Baldus, C. D.
    Brandts, C.
    Kraemer, A.
    Schaefer-Eckart, K.
    Neubauer, A.
    Krause, S. W.
    Giagounidis, A.
    Aulitzky, W.
    Bornhaeuser, M.
    Schaich, M.
    Parmentier, S.
    Thiede, C.
    von Bonin, M.
    Schetelig, J.
    Kramer, M.
    Serve, H.
    Berdel, W. E.
    Ehninger, G.
    ANNALS OF HEMATOLOGY, 2015, 94 : S46 - S47
  • [35] Sorafenib versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SORAML Trial
    Roellig, C.
    Mueller-Tidow, C.
    Huettmann, A.
    Noppeney, R.
    Kunzmann, V.
    Baldus, C. D.
    Brandts, C.
    Kraemer, A.
    Schaefer-Eckart, K.
    Neubauer, A.
    Krause, S. W.
    Giagounidis, A.
    Aulitzky, W.
    Bornhaeuser, M.
    Schaich, M.
    Parmentier, S.
    Thiede, C.
    von Bonin, M.
    Schetelig, J.
    Kramer, M.
    Serve, H.
    Berdel, W. E.
    Ehninger, G.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 46 - 47
  • [36] Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial
    Roelllig, Christoph
    Mueller-Tidow, Carsten
    Huettmann, Andreas
    Noppeney, Richard
    Kunzmann, Volker
    Baldus, Claudia D.
    Brandts, Christian H.
    Kraemer, Alwin
    Schaefer-Eckart, Kerstin
    Neubauer, Andreas
    Krause, Stefan W.
    Giagounidis, Aristoteles
    Aulitzky, Walter E.
    Bornhaeuser, Martin
    Schaich, Markus
    Parmentier, Stefani B.
    Thiede, Christian
    von Bonin, Malte
    Schetelig, Johannes
    Kramer, Michael
    Serve, Hubert
    Berdel, Wolfgang E.
    Ehninger, Gerhard
    BLOOD, 2014, 124 (21)
  • [37] Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial
    Xiangwei Yang
    Hong Chen
    Duanya Xu
    Xianju Chen
    Yamei Li
    Jun Tian
    Dongwen Wang
    Jun Pang
    BMC Cancer, 22
  • [38] Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial
    Yang, Xiangwei
    Chen, Hong
    Xu, Duanya
    Chen, Xianju
    Li, Yamei
    Tian, Jun
    Wang, Dongwen
    Pang, Jun
    BMC CANCER, 2022, 22 (01)
  • [39] High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial
    Lertbutsayanukul, Chawalit
    Kitpanit, Sarin
    Kannarunimit, Danita
    Chakkabat, Chakkapong
    Oonsiri, Sornjarod
    Thephamongkhol, Kullathorn
    Puataweepong, Putipun
    Katanyoo, Kanyarat
    Sukhaboon, Jirasak
    Tovanabut, Chokaew
    Chongsathientham, Sirikanya
    Treeratsapanich, Pornravee
    Soonthornrak, Jirarat
    Prayongrat, Anussara
    TRIALS, 2022, 23 (01)
  • [40] High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial
    Chawalit Lertbutsayanukul
    Sarin Kitpanit
    Danita Kannarunimit
    Chakkapong Chakkabat
    Sornjarod Oonsiri
    Kullathorn Thephamongkhol
    Putipun Puataweepong
    Kanyarat Katanyoo
    Jirasak Sukhaboon
    Chokaew Tovanabut
    Sirikanya Chongsathientham
    Pornravee Treeratsapanich
    Jirarat Soonthornrak
    Anussara Prayongrat
    Trials, 23